In One Stroke, Retrophin Acquires And Licenses Assets For Autism And Schizophrenia, Doubles Down On Oxytocin
This article was originally published in The Pink Sheet Daily
Retrophin, the former rare disease specialist, announced an agreement to acquire Kyalin Biosciences, whose lead candidate is a synthetic oxytocin formulation for autism. On the same day, it licensed another intranasal formulation of oxytocin from Novartis, market-ready for an obstetric indication.
You may also be interested in...
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.